.
Pharm Exec’s annual listing of the top biopharma players shows that most are holding their ground as they weigh a more challenging business climate with new opportunities for growth in a potentially resurgent marketplace
Ver anterior:
Pharm Exec's Top 50 Companies 2018 (I)
miércoles, 12 de septiembre de 2018
Pharm Exec's Top 50 Companies 2018 (II)
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario